The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors

Journal of Pharmaceutical Sciences

Volumn 96, Issue 1, 2007, Pages 209-222

  Mathis, A Scott ^a   Jin, Song ^b   Friedman, Gary S ^c   Peng, Felice ^b   Carl, Stephen M ^d   Knipp, Gregory T ^d  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c International Regenerative Medicine Incorporated   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

ABCA1; Atherosclerosis; CD36; Cyclosporine; LXR; Macrophage scavenger receptors; PPAR; Sirolimus; Tacrolimus

Indexed keywords

ABC TRANSPORTER A1; CYCLOSPORIN; HORMONE RECEPTOR; LIVER X RECEPTOR ALPHA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAPAMYCIN; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR B; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MACROPHAGE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 33846177854     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20751     Document Type: Article

References (28)

1. Krämer BK, Zülke C, Kammerl MC, et al. 2003. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 3:982-987.
2. Kiberd B, Keough-Ryan T, Panek R. 2003. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 3:1393-1399.
3. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. 2002. Immunosuppresssion impact on long-term cardiovascular complications after liver transplantation. Am J Surg 183:595-599.
4. Aakhus S, Dahl K, Wideroe TE. 1999. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14:648-654.
5. Paul LC. 1999. Chronic allograft nephropathy: An update. Kidney Int 56:783-793.
6. Satterthwaite R, Aswad S, Sunga V, et al. 1998. Incidence of new-onset hypercholesterolemia in renal transplant patients with FK506 or cyclosporine. Transplantation 65:446-449.
7. Flechner SM, Goldfarb D, Modlin C, et al. 2002. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of Sirolimus Versus Cyclosporine. Transplantation 74:1070-1076.
8. Ciancio G, Burke GW, Gaynor JJ, et al. 2004. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77:252.
9. Jin S, Mathis AS, Rosenblatt J, et al. 2004. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: Macrophage scavenger receptor regulation. Transplantation 77:497-504.
10. Jin S, Mathis AS, Gioia K, et al. 2004. The effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1 derived human macrophages. Transplantation 77:1281-1287.
11. Linton MF, Fazio S. 2001. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 12:489-495.
12. Febbraio M, Hajjar DP, Silverstein RL. 2001. CD36: A Class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108:785-791.
13. Mathis AS, Dave N, Knipp GT, Friedman GS. 2004. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61:565-585.
14. Chawla A, Boisvert WA, Lee CH, et al. 2001. A PPAR-gamma-LXR-ABCA1 pathways in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171.
15. Elloso MM, Azrolan N, Sehgal SN, et al. 2003. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in Apo E-deficient mice. Am J Transplant 3:562-56.
16. van Dam MJ, de Groot E, Clee SM, et al. 2002. Association between increased arterial-wall thickness and impairment of ABCA1-driven cholesterol efflux: An Observational Study. Lancet 359:37-42.
17. Blum CB. 2002. Effects of sirolimus on lipids in renal allograft recipients: An analysis using the framingham risk model. Am J Transplant 2:551-559.
18. Liew YY, Docter E, Ray DW, Hutchinson IV, Brogan IJ. 2002. Effects of rapamycin and prednisolone in differentiated THP-1 and U937 cells. Transplant Proc 34:2872-2873.
19. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. 1999. Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int 56:440-451.
20. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. 2005. Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 289:F43-F48.
21. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. 2000. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531.
22. Serruys PW, Kutyrk MJB, Ong ATL. 2006. Coronary-artery stents. N Engl J Med 354:483-495.
23. Araki M, Flechner SM, Ismail HR, et al. 2006. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 81:335-341.
24. Romagnoli J, Citterio F, Nanni G, et al. 2006. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transpl Proc 38:1034-1036.
25. Kumar MSA, Heifets M, Fyfe B, et al. 2005. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation. 80:807-814.
26. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. 2001. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72:777-786.
27. Singaraja RR, Fievet C, Castro G, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 110:35-42.
28. Ricote M, Welch JS, Glass CK. 2000. Regulation of macrophage gene expression by peroxisome proliferator-activated receptor-γ. Horm Res 54:275-280.